News
Our news highlights key developments at leadXpro, including new partnerships, collaborations, and company milestones that drive our mission forward. Follow us on LinkedIn for our most recent updates and news.
Nuclera and leadXpro partner to accelerate structure-based drug design for complex membrane proteins
Partex.AI and leadXpro announce collaboration to expand indications and support out-licensing of A2BR antagonist program
New collaboration between leadXpro and Orbion
leadXpro and Alipheron are combining their cutting-edge technologies to bring a new level of innovation to early drug discovery
Cumulus Oncology and leadXpro achieve critical milestone in GPR68 drug discovery project
Golgi Neurosciences and leadXpro announce collaboration on GPR65 modulators
Cumulus Oncology and leadXpro collaborate to develop small molecules against novel cancer-focused GPCR targets
AXXAM bootcamp webinar in collaboration with leadXpro
RaQualia Pharma and leadXpro collaborate to accelerate drug discovery on intractable membrane protein targets
Septerna engages leadXpro to discover novel binding partners to GPCR Targets for use in internal drug discovery programs
First CrySol VitroJet in Switzerland
leadXpro has just elucidated the world’s first structure of a proton-sensing GPCR target
Colocalized targeting of TGF-beta and PD-L1 by bintrafusp alfa elicits distinct antitumor responses
Five opportunities at the interface between structural biology and AI, and their Impact on drug discovery
leadXpro joins the MabDesign network
First structure of human Kv3.1 channel
CryoEM structure of Lipopolysaccharide Transporter LptDE opens the door to antibiotics design
First Cryo-EM structure of the human TRPV4 ion-channel in the open conformation, in complex with an agonist.
Selective Antagonists of the A2B Adenosine Receptor
leadXpro celebrates its 5th anniversary
Axxam, leadXpro and MercachemSyncom form a strategic alliance for structure-based drug discovery services
Enabling design of selective antagonists for the CC Chemokine receptor 2A (CCR2A)
Transforming drug discovery on membrane proteins
leadXpro produces protein for COVID-19 research campaign
leadXpro, first tenant of Park Innovaare’s innovation campus
leadXpro and Lundbeck partner for membrane protein structure research
leadXpro and Astex enter partnership on membrane protein structure research
leadXpro licenses cryoSPARC™ software
Symposium on Drug Discovery @ SwissFEL
Collaboration with Sanofi on cryo-EM based structure research
First biomolecular structure experiment at SwissFEL
Collaboration with the University of Zürich on membrane protein targeted sybodies
Collaboration with InterAx on new immune oncology drugs
Watch our 2nd anniversary video
CTI grants leadXpro startup label
BASF and leadXpro announce research collaboration
leadXpro scientists chart the future of structure based drug discovery
leadXpro adopts Creoptix’ wave technology for ligand characterization
leadXpro and AXXAM collaborate on novel inflammatory GPCR target
New operational space and funding ensures further growth of leadXpro
GPCR-ligand complex structure within 4 months
leadXpro enters collaboration on cryo-EM based new lead discovery with Bayer
Park Innovaare files building application for leadXpro’s future home
leadXpro and Boehringer Ingelheim collaborate on membrane protein drug target
leadXpro celebrates its first anniversary
leadXpro and Paul Scherrer Institute sign agreement on Beam Line at the Swiss Light Source
Further development of Serial Crystallography
Heptares and leadXpro enter collaboration on GPCR biostructure